| 2/6/2014 | PP | Novelos Therapeutics arranges $4 million placement of 8% convertibles
|
| 2/15/2013 | PP | Novelos Therapeutics arranges $5.5 million private placement of units
|
| 2/13/2013 | PP | Novelos Therapeutics prices $5.5 million public sale of units at $0.50
|
| 11/20/2012 | PP | Novelos Therapeutics reports plans to price public offering of units
|
| 11/5/2012 | PP | Novelos Therapeutics completes $2 million private placement of stock
|
| 6/8/2012 | PP | Novelos Therapeutics prices $5.42 million public sale of equity units
|
| 4/9/2012 | PP | Novelos Therapeutics intends to price public offering of common stock
|
| 12/2/2011 | PP | Novelos Therapeutics lifts public offering of units to $6.05 million
|
| 12/1/2011 | PP | Novelos Therapeutics arranges $5.9 million public offering of units
|
| 7/1/2011 | PP | Novelos Therapeutics will price $15 million public offering of stock
|
| 4/11/2011 | PP | Novelos Therapeutics wraps $5.13 million private placement of units
|
| 11/30/2010 | PP | Novelos exchanges all series E, series C preferreds for common stock
|
| 7/22/2010 | PP | New Issue: Novelos orchestrates $1.5 million registered direct offering of stock
|
| 11/12/2009 | PP | New Issue: Novelos Therapeutics settles $9 million placement of stock, warrants
|
| 11/12/2009 | PP | Market Commentary: East West seals $500 million; MAP secures credit facility; Novelos closes $9 million financing
|
| 8/26/2009 | PP | Market Commentary: Noront settles stock sale; North American Galvanizing issues notes; Novelos secures $9 million
|
| 8/26/2009 | PP | New Issue: Novelos secures $9 million from private placement of shares, warrants
|
| 2/12/2009 | PP | New Issue: Novelos raises $10 million in placement of convertible preferreds
|
| 8/18/2008 | PP | Market Commentary: Cheniere raises $250 million; Synchronica gets £5.08 million from stock; Novelos pockets $3 million
|
| 8/18/2008 | PP | New Issue: Novelos pockets $3 million from private placement of shares
|
| 4/11/2008 | PP | New Issue: Novelos pockets $5.68 million from private placement of convertible preferreds, warrants
|
| 3/27/2008 | PP | New Issue: Novelos secures $5 million from private placement of convertible preferreds, warrants
|
| 3/27/2008 | PP | Market Commentary: Avanir plans $40 million offering; Modigene gets $12 million; Novelos prices $5 million of stock
|
| 4/16/2007 | PP | Market Commentary: Feldman Mall to settle $50 million deal; Viragen pockets $3 million from convertible preferreds
|
| 4/13/2007 | PP | New Issue: Novelos Therapeutics sells $15 million convertible preferreds
|
| 4/13/2007 | PP | Market Commentary: Novelos Therapeutics secures $15 million from preferreds; EnerJex closes $9 million PIPE
|
| 9/27/2006 | BT | Market Commentary: Nabi hires BofA, up after hours; Millennium off; BioSante dives 14.5%; BioCryst, Novavax gain
|
| 9/11/2006 | BT | Novelos gets notice of allowance for fifth U.S. patent
|
| 8/7/2006 | BT | Novelos' lung-cancer treatment NOV-002 gets fast-track status
|
| 7/18/2006 | BT | Novelos enrolls first patient in phase 2 ovarian cancer trial
|
| 6/26/2006 | BT | Government OKs Novelos' initial proposal for NOV-002 in treatment of radiation exposure
|
| 5/30/2006 | BT | Novelos finalizes phase 3 trial protocol for NOV-002 in non-small cell lung cancer with FDA
|
| 4/24/2006 | BT | Novelos gets FDA OK of Investigational New Drug application for hepatitis C drug
|
| 3/22/2006 | BT | Novelos files IND for novel hepatitis C drug, NOV-205
|
| 3/8/2006 | BT | Novelos files SPA with the FDA for phase 3 development in lung cancer
|
| 3/3/2006 | PP | Market Commentary: North American Palladium plans $58.5 million note offering; CytRx prepares to close $13.42 million PIPE
|
| 3/2/2006 | PP | Market Commentary: Novelos prepares to close $15.05 million stock deal; MediGene plans €15.63 million PIPE
|
| 3/2/2006 | BTPP | New Issue: Novelos Therapeutics negotiates $12.86 million stock sale, upsizes to $15.05 million
|
| 12/5/2005 | BT | Novelos: FDA says single phase 3 trial sufficient to license NOV-002 to treat lung cancer
|
| 11/8/2005 | BT | Novelos forms collaboration with Shriners Hospitals to confirm positive NOV-002 data
|
| 11/8/2005 | BTPP | Novelos may return to PIPE market for additional funding
|
| 11/3/2005 | BTPP | New Issue: Novelos Therapeutics raises additional $200,000 from convertible preferreds offering
|
| 10/24/2005 | BT | Novelos to meet FDA on Dec. 2 to discuss results, propose phase 3 trial for lung cancer drug
|
| 10/6/2005 | BT | Novelos seeks Archipelago listing
|
| 10/3/2005 | BTPP | New Issue: Novelos completes $3 million private placement of convertibles
|
| 8/1/2005 | PP | Market Commentary: Inverness secures $95 million from stock deal; PIPE volume suffers from earnings
|
| 8/1/2005 | BTPP | New Issue: Novelos wraps $4.15 million private placement of units
|
